PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer

Ying Wu,Zhe Wang,Lu Han,Zhihao Guo,Bohua Yan,Lili Guo,Huadong Zhao,Mengying Wei,Niuniu Hou,Jing Ye,Zhe Wang,Changhong Shi,Suling Liu,Ceshi Chen,Suning Chen,Ting Wang,Jun Yi,JianPing Zhou,Libo Yao,Wenxia Zhou,Rui Ling,Jian Zhang
DOI: https://doi.org/10.1016/j.ymthe.2022.03.003
IF: 12.91
2022-03-01
Molecular Therapy
Abstract:Cancer cells respond to various stressful conditions through the dynamic regulation of RNA m6A modification. Doxorubicin is a widely used chemotherapeutic drug that induces DNA damage. It is interesting to know whether cancer cells regulate the DNA damage response and doxorubicin sensitivity through RNA m6A modification. Here, we found that doxorubicin treatment significantly induced RNA m6A methylation in breast cancer cells in both a dose- and a time-dependent manner. However, protein arginine methyltransferase 5 (PRMT5) inhibited RNA m6A modification under doxorubicin treatment by enhancing the nuclear translocation of the RNA demethylase AlkB homolog 5 (ALKBH5), which was previously believed to be exclusively localized in the nucleus. Then, ALKBH5 removed the m6A methylation of BRCA1 for mRNA stabilization and further enhanced DNA repair competency to decrease doxorubicin efficacy in breast cancer cells. Importantly, we identified the approved drug tadalafil as a novel PRMT5 inhibitor that could decrease RNA m6A methylation and increase doxorubicin sensitivity in breast cancer. The strategy of targeting PRMT5 with tadalafil is a promising approach to promote breast cancer sensitivity to doxorubicin through RNA methylation regulation.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?